GB2610815A - Compounds - Google Patents

Compounds Download PDF

Info

Publication number
GB2610815A
GB2610815A GB2113117.2A GB202113117A GB2610815A GB 2610815 A GB2610815 A GB 2610815A GB 202113117 A GB202113117 A GB 202113117A GB 2610815 A GB2610815 A GB 2610815A
Authority
GB
United Kingdom
Prior art keywords
group
compound
compound according
groups
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB2113117.2A
Other languages
English (en)
Other versions
GB202113117D0 (en
Inventor
Whiteman Matthew
Torregrossa Roberta
Wood Mark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitorx Therapeutics Ltd
Original Assignee
Mitorx Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitorx Therapeutics Ltd filed Critical Mitorx Therapeutics Ltd
Priority to GB2113117.2A priority Critical patent/GB2610815A/en
Publication of GB202113117D0 publication Critical patent/GB202113117D0/en
Priority to AU2022347098A priority patent/AU2022347098A1/en
Priority to CN202280075238.3A priority patent/CN118234716A/zh
Priority to CA3231394A priority patent/CA3231394A1/en
Priority to MX2024003214A priority patent/MX2024003214A/es
Priority to EP22777195.3A priority patent/EP4396174A1/en
Priority to KR1020247012225A priority patent/KR20240108380A/ko
Priority to JP2024516411A priority patent/JP2024535017A/ja
Priority to US18/691,650 priority patent/US20240400536A1/en
Priority to PCT/GB2022/052325 priority patent/WO2023041906A1/en
Publication of GB2610815A publication Critical patent/GB2610815A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/38—Amides of thiocarboxylic acids
    • C07C327/48—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to carbon atoms of six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
GB2113117.2A 2021-09-14 2021-09-14 Compounds Withdrawn GB2610815A (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GB2113117.2A GB2610815A (en) 2021-09-14 2021-09-14 Compounds
PCT/GB2022/052325 WO2023041906A1 (en) 2021-09-14 2022-09-14 Idebenone derivatives and their use in treating plants
MX2024003214A MX2024003214A (es) 2021-09-14 2022-09-14 Derivados de idebenona y su uso en el tratamiento de plantas.
CN202280075238.3A CN118234716A (zh) 2021-09-14 2022-09-14 艾地苯醌衍生物及其在治疗植物中的用途
CA3231394A CA3231394A1 (en) 2021-09-14 2022-09-14 Idebenone derivatives and their use in treating plants
AU2022347098A AU2022347098A1 (en) 2021-09-14 2022-09-14 Idebenone derivatives and their use in treating plants
EP22777195.3A EP4396174A1 (en) 2021-09-14 2022-09-14 Idebenone derivatives and their use in treating plants
KR1020247012225A KR20240108380A (ko) 2021-09-14 2022-09-14 이데베논 유도체 및 식물의 치료에서의 그의 용도
JP2024516411A JP2024535017A (ja) 2021-09-14 2022-09-14 イデベノン誘導体及び植物の処置におけるそれらの使用
US18/691,650 US20240400536A1 (en) 2021-09-14 2022-09-14 Idebenone derivatives and their use in treating plants

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2113117.2A GB2610815A (en) 2021-09-14 2021-09-14 Compounds

Publications (2)

Publication Number Publication Date
GB202113117D0 GB202113117D0 (en) 2021-10-27
GB2610815A true GB2610815A (en) 2023-03-22

Family

ID=78149340

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2113117.2A Withdrawn GB2610815A (en) 2021-09-14 2021-09-14 Compounds

Country Status (10)

Country Link
US (1) US20240400536A1 (https=)
EP (1) EP4396174A1 (https=)
JP (1) JP2024535017A (https=)
KR (1) KR20240108380A (https=)
CN (1) CN118234716A (https=)
AU (1) AU2022347098A1 (https=)
CA (1) CA3231394A1 (https=)
GB (1) GB2610815A (https=)
MX (1) MX2024003214A (https=)
WO (1) WO2023041906A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025104452A1 (en) 2023-11-17 2025-05-22 Mitorx Therapeutics Ltd Compounds for use in treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005019232A1 (en) * 2003-08-22 2005-03-03 Antipodean Pharmaceuticals, Inc. Mitoquinone derivatives used as mitochondrially targeted antioxidants
US8263094B2 (en) 2008-09-23 2012-09-11 Eastman Chemical Company Esters of 4,5-disubstituted-oxy-2-methyl-3,6-dioxo-cyclohexa-1,4-dienyl alkyl acids and preparation thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005019232A1 (en) * 2003-08-22 2005-03-03 Antipodean Pharmaceuticals, Inc. Mitoquinone derivatives used as mitochondrially targeted antioxidants
US8263094B2 (en) 2008-09-23 2012-09-11 Eastman Chemical Company Esters of 4,5-disubstituted-oxy-2-methyl-3,6-dioxo-cyclohexa-1,4-dienyl alkyl acids and preparation thereof

Non-Patent Citations (49)

* Cited by examiner, † Cited by third party
Title
"Handbook of Pharmaceutical Excipients", 1994
"Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING COMPANY
AHMAD A ET AL., SHOCK, vol. 45, no. 1, 2016, pages 88 - 97
AHMAD ET AL., ACUTE RENAL INJURY, 2016
AHMAD ET AL., BURN INJURY, 2016
BERGE SM ET AL., J PHARM SCI, vol. 66, no. 1, 1977, pages 1 - 19
BERGE: "Pharmaceutically Acceptable Salts", J. PHARM. SCI., vol. 66, 1977, pages 1 - 19
BERGE: "Pharmaceutically Acceptable Salts", J. PHARM. SCI.., vol. 66, 1977, pages 1 - 19
CHATZIANASTASIOU A ET AL., J PHARMACOL EXP THER, vol. 358, no. 3, 2016, pages 431 - 440
CHRISTIAN, CJBENIAN GM, AGING CELL, vol. 19, no. 10, 2020, pages e13223
COVARRUBIAS AE ET AL., AM J PATHOL, vol. 189, no. 1, 2019, pages 104 - 114
DRUCKER ET AL., NECROTIZING ENTEROCOLITIS, 2018
DRUCKER NA ET AL., J PEDIATR SURG., vol. 53, no. 9, 2018, pages 1692 - 1698
ELLWOD RA ET AL., PROC NATL ACAD SCI USA, vol. 118, no. 9, 2021, pages e2018342118
ELLWOOD ET AL., DUCHENNE MUSCULAR DYSTROPHY, 2021
ESCRIBANO-LOPEZ I ET AL., CELL PHYSIOL BIOCHEM, vol. 52, no. 2, 2019, pages 186 - 197
FOX BC ET AL., J INHERIT METAB DIS, vol. 44, no. 2, 2020, pages 367 - 375
FOX ET AL., LEIGH SYNDROME, PRIMARY MITOCHONDRIAL DISEASE, 2020
GERO D ET AL., PHARMACOL RES, vol. 113, no. pt. A, 2016, pages 186 - 198
GERO ET AL., DIABETIC VASCULAR DISEASE, 2016
IKEDA ET AL., NEUROLOGICAL DAMAGE POST CARDIAC ARREST, 2015
IKEDA K ET AL., NITRIC OXIDE, vol. 46, 2015, pages 131 - 144
JURIASINGANI S ET AL., NITRIC OXIDE, vol. 81, 2018, pages 57 - 66
KARAMAN ET AL., COPD, AIRWAY INFLAMMATION, 2020
KARAMAN Y ET AL., BASIC CLIN PHARMACOL TOXICOL, vol. 128, no. 5, 2021, pages 652 - 660
KARWI QG ET AL., BR J PHARMACOL, vol. 174, no. 4, 2017, pages 287 - 301
LATORRE E ET AL., AGING, vol. 10, no. 7, 2018, pages 1666 - 1681
LATORRE ET AL., CARDIOVASCULAR DYSFUNCTION, 2018
LOBB I ET AL., AM J TRANSPLANT, vol. 17, no. 2, 2017, pages 341 - 352
MONTENEGRO LUCIA ET AL: "In Vitro Antioxidant Activity of Idebenone Derivative-Loaded Solid Lipid Nanoparticles", MOLECULES, vol. 22, no. 6, 1 January 2017 (2017-01-01), DE, pages 887, XP055916757, ISSN: 1433-1373, DOI: 10.3390/molecules22060887 *
NISHIME ET AL., PANCREATIC ISLET TRANSPLANT, 2020
NISHIME K ET AL., AM J TRANSPLANT, 2020
OH K. H.KIM H., PROC. NATL. ACAD. SCI. U.S.A., vol. 110, 2013, pages 19024 - 19029
POREDOS P ET AL., ANGIOLOGY, 2021
PRE-ECLAMPSIA
QIN LI-XIA ET AL: "Coenzyme Q Functionalized CdTe/ZnS Quantum Dots for Reactive Oxygen Species (ROS) Imaging", CHEMISTRY - A EUROPEAN JOURNAL, vol. 17, no. 19, 2 May 2011 (2011-05-02), DE, pages 5262 - 5271, XP055916760, ISSN: 0947-6539, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1002/chem.201003749> DOI: 10.1002/chem.201003749 *
SALMON-CHEMIN L ET AL., J MED CHEM, vol. 44, no. 4, 2001, pages 548 - 565
SANCHEZ-ARANGUREN LC ET AL., SCI REP, vol. 10, 2020, pages 15810
SUGIYAMA YFUJITA T, FEBS LETT., vol. 184, no. 1, 1985, pages 48 - 51
SZCZESNY B ET AL., NITRIC OXIDE, vol. 41, 2014, pages 120 - 130
SZCZESNY BARTOSZ ET AL: "AP39, a novel mitochondria-targeted hydrogen sulfide donor, stimulates cellular bioenergetics, exerts cytoprotective effects and protects against the loss of mitochondrial DNA integrity in oxidatively stressed endothelial cells in vitro", NITRIC OXIDE: BIOLOGY AND CHEMISTRY., vol. 41, 1 September 2014 (2014-09-01), AMSTERDAM, NL, pages 120 - 130, XP055916763, ISSN: 1089-8603, DOI: 10.1016/j.niox.2014.04.008 *
T. GREENP. WUTS: "Protective Groups in Organic Synthesis", 1999, JOHN WILEY AND SONS
TOMASOVA, HYPERTENSION, 2015
WEPLER ET AL., BLUNT CHEST TRAUMA AND HAEMORRHAGIC SHOCK, 2019
WEPLER M ET AL., SHOCK, vol. 52, no. 2, 2019, pages 230 - 239
ZHAO ET AL., ALZHEIMER'S DISEASE, 2016
ZHAO F-L ET AL., OXID MED CELL LONGEV, 2016, pages 8360738
ZHU C ET AL., AM J TRANSPLANT, vol. 19, no. 11, 2019, pages 3139 - 3148
ZHU ET AL., CARDIAC TRANSPLANT, 2019

Also Published As

Publication number Publication date
CN118234716A (zh) 2024-06-21
MX2024003214A (es) 2024-07-30
CA3231394A1 (en) 2023-03-23
KR20240108380A (ko) 2024-07-09
EP4396174A1 (en) 2024-07-10
GB202113117D0 (en) 2021-10-27
AU2022347098A1 (en) 2024-04-04
WO2023041906A1 (en) 2023-03-23
US20240400536A1 (en) 2024-12-05
JP2024535017A (ja) 2024-09-26

Similar Documents

Publication Publication Date Title
CA2423744C (en) Hydroxamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
US11786533B2 (en) Use of EZH2 inhibitors for treating cancer
US5736576A (en) Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
EP1441716B1 (en) Alkane diol derivatives as therapeutic agents for the treatment of bone conditions
JP2003535123A (ja) 治療薬としてのバルビツール酸類似体
EP3233842B1 (en) Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (rarb) agonists
JP2005511556A6 (ja) 骨疾患の処置のための治療薬としてのアルカンジオール誘導体
CA3185793A1 (en) Isoquinoline compounds and their use in treating ahr imbalance
WO2007029021A1 (en) 1,5-substituted tetrazoles as therapeutic compounds
JP2016185947A (ja) ＩＲＥ−１αインヒビター
US20100028262A1 (en) 3,4-methylenedioxy-substituted chalcones as therapeutic agents
AU2002317303B2 (en) 4-aryl quinols and analogs thereof as therapeutic agents
GB2610815A (en) Compounds
ES2222988T3 (es) Formas de sal especificas de derivados de trifeniletileno como moduladores selectivos de los receptores de estrogenos.
ES2369510T3 (es) Moduladores del receptor de la vitamina d.
JP5042015B2 (ja) 骨状態を治療するための治療薬としてのアリールアルキルスルホンアミド類
US7112698B2 (en) 4-(c2-6alkoxy)-substituted chalcones as therapeutic agents
US20040063739A1 (en) N8, n13 -disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents
WO2025104452A1 (en) Compounds for use in treatment
CN107304199B (zh) 一种新的喜巴辛类似物及其在医药中的应用
JP2015522604A (ja) ヨウ化ナトリウム共輸送体の阻害剤としてのジヒドロピリミジン−２（１ｈ）−オン類およびジヒドロピリミジン−２（１ｈ）−チオン類
BRPI0607547A2 (pt) uso de compostos, compostos, composição farmacêutica, e, método de preparar a mesma

Legal Events

Date Code Title Description
COOA Change in applicant's name or ownership of the application

Owner name: MITORX THERAPEUTICS LTD

Free format text: FORMER OWNER: UNIVERSITY OF EXETER

WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)